Silence Therapeutics plc (NASDAQ:SLN) Receives $57.20 Average Price Target from Brokerages

Shares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have received an average rating of "Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $57.20.

A number of equities analysts recently weighed in on the stock. Chardan Capital reissued a "buy" rating and set a $55.00 target price on shares of Silence Therapeutics in a research note on Tuesday. Jefferies Financial Group initiated coverage on shares of Silence Therapeutics in a research report on Tuesday, September 3rd. They set a "buy" rating and a $40.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Monday, December 9th. BMO Capital Markets reiterated an "outperform" rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Finally, William Blair restated an "outperform" rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Values First Advisors Inc. bought a new stake in Silence Therapeutics in the 3rd quarter worth about $56,000. Y Intercept Hong Kong Ltd increased its position in shares of Silence Therapeutics by 22.9% during the third quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company's stock valued at $383,000 after acquiring an additional 3,923 shares during the last quarter. Quarry LP bought a new stake in Silence Therapeutics during the second quarter worth $114,000. Marshall Wace LLP boosted its position in Silence Therapeutics by 7.3% in the second quarter. Marshall Wace LLP now owns 149,397 shares of the company's stock worth $2,839,000 after purchasing an additional 10,206 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in Silence Therapeutics in the 3rd quarter valued at $207,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Stock Down 2.3 %

NASDAQ SLN traded down $0.15 on Friday, hitting $6.45. The company's stock had a trading volume of 281,372 shares, compared to its average volume of 267,002. The company's 50-day moving average is $13.69 and its 200 day moving average is $17.14. The firm has a market cap of $193.04 million, a PE ratio of -4.11 and a beta of 1.05. Silence Therapeutics has a 1-year low of $5.81 and a 1-year high of $27.72.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.